Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Julio Cesar Aguilar"'
Autor:
Eduardo Armando Sutta Gonzales, Christian Larry Salazar Bobadilla, Julio Cesar Aguilar Uñapilco, David Huittoccollo Quispe
Publikováno v:
Innovación y Software, Vol 3, Iss 1, Pp 67-80 (2022)
En el presente artículo se va a utilizar la técnica Desing Thinking para solucionar y evaluar el problema de la selección de métricas de calidad de un software, considerando algunas técnicas para la recopilación de las ideas que puedan dar sopo
Externí odkaz:
https://doaj.org/article/88fcb2b903b04666a1130619dbded4f4
Autor:
Kana Shiraishi, Osamu Yoshida, Yusuke Imai, Sheikh Mohammad Fazle Akbar, Takahiro Sanada, Michinori Kohara, Takashi Miyazaki, Taizou Kamishita, Teruki Miyake, Masashi Hirooka, Yoshio Tokumoto, Masanori Abe, Julio Cesar Aguilar Rubido, Gerardo Guillen Nieto, Yoichi Hiasa
Publikováno v:
Vaccines, Vol 11, Iss 9, p 1479 (2023)
Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vacci
Externí odkaz:
https://doaj.org/article/198fc98d553b4e0e9cc98cbf8ac411b9
Autor:
Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Guillen Nieto Gerardo, Yoichi Hiasa
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionThere is a pressing need to develop novel drugs for treating patients with chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety and efficacy concerns.MethodsA phase III clinical trial was conducted
Externí odkaz:
https://doaj.org/article/4d668348bfe04a3f9683dcea779cc8d2
Autor:
Mamun Al-Mahtab, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Julio Cesar Aguilar, Gerardo Guillen, Yoichi Hiasa
Publikováno v:
Vaccines, Vol 11, Iss 5, p 962 (2023)
An open-level, randomized and treatment-controlled clinical trial has shown that a therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) is endowed with antiviral and liver protecting capacit
Externí odkaz:
https://doaj.org/article/8dba0e8a18024e1cac7bd42aa618c4ca
Publikováno v:
Vaccines, Vol 10, Iss 12, p 2087 (2022)
Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a di
Externí odkaz:
https://doaj.org/article/af0b7cbda2584c0bb606a0c1390e3305
Autor:
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Md. Helal Uddin, Md. Sakirul Islam Khan, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Publikováno v:
Exploration of Medicine, Vol 2, Iss 5 (2021)
With the advent of various vaccines and antimicrobial agents during the 20th century, the control and containment of infectious diseases appeared to be a matter of time. However, studies unveiled the diverse natures of microbes, their lifestyle, and
Externí odkaz:
https://doaj.org/article/033e1893745c488bb147f8f8ef680c78
Autor:
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Sakirul Khan, Osamu Yoshida, Julio Cesar Aguilar, Guillen Nieto Gerardo, Yoichi Hiasa
Publikováno v:
Vaccines, Vol 10, Iss 5, p 746 (2022)
Chronic hepatitis B (CHB) is a highly complicated pathological process in which the disease is initiated by the hepatitis B virus (HBV); however, host immune responses are primarily responsible for variable extents of liver damage. If the patients wi
Externí odkaz:
https://doaj.org/article/76b081c806c94747a5cdaafe3f3e8d43
Autor:
Julio Cesar Aguilar Rubido
Publikováno v:
Future Science OA, Vol 5, Iss 10 (2019)
Externí odkaz:
https://doaj.org/article/0db988432c404023b49871913e78a8e5
Autor:
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Publikováno v:
Vaccines, Vol 10, Iss 1, p 45 (2021)
The objective of the present study was to assess the safety and efficacy of a therapeutic vaccine containing both HBsAg and HBcAg (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT) as a follow-up of a pha
Externí odkaz:
https://doaj.org/article/0999834673a040eb8ee7b7a57ef56cc7
Autor:
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Publikováno v:
Pathogens, Vol 10, Iss 11, p 1440 (2021)
A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NA
Externí odkaz:
https://doaj.org/article/2121e5c663214e4da03bd2d7a3be6939